The article "Enhancement of Specialized Metabolites using CRISPR/Cas Gene Editing Technology in Medicinal Plants" by Swati Das, Moonhyuk Kwon, and Jae-Year Kim explores the potential of CRISPR/Cas gene editing technology to enhance the production of specialized metabolites in medicinal plants. The authors highlight the importance of these plants in providing therapeutic and pharmacological benefits, such as antitumor, antimicrobial, and anticancer compounds. They discuss the classification of plant metabolites into primary and secondary (specialized) metabolites and emphasize the role of CRISPR/Cas9 in targeted genome editing, which can introduce double-strand breaks (DSBs) at specific sites to modify gene expression and enhance the biosynthesis of desired metabolites. The review covers the current status of plant metabolic engineering using CRISPR/Cas technology, including the enhancement of carotenoid and lycopene accumulation in rice and tomato, the increase in GABA levels in rice and tomato, and the improvement of provitamin D3 levels in tomatoes. It also discusses the manipulation of anthocyanin biosynthesis and the enhancement of vitamin C content in plants through CRISPR/Cas9. The article further delves into the application of CRISPR/Cas technology in medicinal plants, such as *Atropa belladonna* for enhancing hyoscyamine production, *Dendrobium officinale* for improving lignocellulose biosynthesis, and *Nicotiana tabacum* for reducing nicotine levels. The authors provide detailed examples of how CRISPR/Cas9 has been used to target specific genes involved in the biosynthesis of valuable metabolites, demonstrating the potential of this technology in enhancing the pharmaceutical and commercial value of medicinal plants. Overall, the article underscores the significance of CRISPR/Cas gene editing in advancing the field of plant metabolic engineering, particularly in the context of medicinal plants, by providing a comprehensive overview of the current state and future prospects of this technology.The article "Enhancement of Specialized Metabolites using CRISPR/Cas Gene Editing Technology in Medicinal Plants" by Swati Das, Moonhyuk Kwon, and Jae-Year Kim explores the potential of CRISPR/Cas gene editing technology to enhance the production of specialized metabolites in medicinal plants. The authors highlight the importance of these plants in providing therapeutic and pharmacological benefits, such as antitumor, antimicrobial, and anticancer compounds. They discuss the classification of plant metabolites into primary and secondary (specialized) metabolites and emphasize the role of CRISPR/Cas9 in targeted genome editing, which can introduce double-strand breaks (DSBs) at specific sites to modify gene expression and enhance the biosynthesis of desired metabolites. The review covers the current status of plant metabolic engineering using CRISPR/Cas technology, including the enhancement of carotenoid and lycopene accumulation in rice and tomato, the increase in GABA levels in rice and tomato, and the improvement of provitamin D3 levels in tomatoes. It also discusses the manipulation of anthocyanin biosynthesis and the enhancement of vitamin C content in plants through CRISPR/Cas9. The article further delves into the application of CRISPR/Cas technology in medicinal plants, such as *Atropa belladonna* for enhancing hyoscyamine production, *Dendrobium officinale* for improving lignocellulose biosynthesis, and *Nicotiana tabacum* for reducing nicotine levels. The authors provide detailed examples of how CRISPR/Cas9 has been used to target specific genes involved in the biosynthesis of valuable metabolites, demonstrating the potential of this technology in enhancing the pharmaceutical and commercial value of medicinal plants. Overall, the article underscores the significance of CRISPR/Cas gene editing in advancing the field of plant metabolic engineering, particularly in the context of medicinal plants, by providing a comprehensive overview of the current state and future prospects of this technology.